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Abstract
Background: MTG16, MTGR1 and ETO are nuclear transcriptional corepressors of the human ETO protein family.
MTG16 is implicated in hematopoietic development and in controlling erythropoiesis/megakaryopoiesis.
Furthermore, ETO homologue genes are 3’participants in leukemia fusions generated by chromosomal
translocations responsible of hematopoietic dysregulation. We tried to identify structural and functional promoter
elements of MTG16 and MTGR1 genes in order to find associations between their regulation and hematopoiesis.
Results: 5’ deletion examinations and luciferase reporter gene studies indicated that a 492 bp sequence upstream of
the transcription start site is essential for transcriptional activity by the MTG16 promoter. The TATA- and CCAAT-less
promoter with a GC box close to the start site showed strong reporter activity when examined in erythroid/
megakaryocytic cells. Mutation of an evolutionary conserved GATA -301 consensus binding site repressed promoter
function. Furthermore, results from in vitro antibody-enhanced electrophoretic mobility shift assay and in vivo
chromatin immunoprecipitation indicated binding of GATA-1 to the GATA -301 site. A role of GATA-1 was also
supported by transfection of small interfering RNA, which diminished MTG16 expression. Furthermore, expression of
the transcription factor HERP2, which represses GATA-1, produced strong inhibition of the MTG16 promoter reporter
consistent with a role of GATA-1 in transcriptional activation. The TATA-less and CCAAT-less MTGR1 promoter
retained most of the transcriptional activity within a -308 to -207 bp region with a GC-box-rich sequence containing
multiple SP1 binding sites reminiscent of a housekeeping gene with constitutive expression. However, mutations of
individual SP1 binding sites did not repress promoter function; multiple active SP1 binding sites may be required to
safeguard constitutive MTGR1 transcriptional activity. The observed repression of MTG16/MTGR1 promoters by the
leukemia associated AML1-ETO fusion gene may have a role in hematopoietic dysfunction of leukemia.
Conclusions: An evolutionary conserved GATA binding site is critical in transcriptional regulation of the MTG16
promoter. In contrast, the MTGR1 gene depends on a GC-box-rich sequence for transcriptional regulation and
possible ubiquitous expression. Our results demonstrate that the ETO homologue promoters are regulated
differently consistent with hematopoietic cell-type- specific expression and function.
Background
The highly conserved ETO (Eight-Twenty-One) corepres-
sor gene family traced to Drosophila ETO homologue
Nervy [1] contains the myeloid translocation gene (MTG)
16 (MTG16) (gene name CBFA2T3)o rm u r i n eETO-2
(gene name cbfa2t3), MTG8 (gene name CBFA2T1,
RUNXT1, ETO)a n dM T G - r e l a t e dp r o t e i n1( MTGR1)
(gene name CBFA2T2). The ETO homologues do not
bind directly to DNA but rather function as protein scaf-
folds and bring about gene repression indirectly through
an interplay with multiple transcriptional regulatory pro-
teins [2,3]. MTG16 has been shown to interact with cano-
nical transcription factors such as PLZF, BCL6, TAL1/
SCL, Gfi1and Heb [4-9], and MTGR1 with TAL1/SCL
[10]. The ETO homologues also recruite chromatin regu-
lating proteins such as nuclear corepressors [3,11,12] and
histone deacetylases (HDACs) that catalyze chromatin
modifications, resulting in transcriptional repression.
Importantly, ETO homologue genes are involved in
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the generation of the AML1- MTG16 fusion gene of t
(16;21) [13] in patients with therapy-induced leukemia,
ETO in the generation of the AML1-ETO fusion gene of t
(8;21) [14,15] and MTGR1 in the generation of AML1-
MTGR1 fusion gene of t(20;21) [16]. The leukemic fusion
proteins so encoded disrupt normal function of transcrip-
tional regulators, to promote dysregulation of hematopoie-
tic cell differentiation [17].
Expression of the MTG16 (murine ETO-2) corepressor
is confined to early hematopoiesis whereas MTGR1 is pre-
sent throughout hematopoietic maturation [18]. Thus,
ETO-2 increases during differentiation of murine embryo-
nic stem cells into hematopoietic cells [19] suggesting a
role in the development of the blood cell compartment.
This is consistent with MTG16 being the most highly
expressed ETO h o m o l o g u eg e n ei nt h es t e m / p r o g e n i t o r
cell compartment [18]. Furthermore, MTG16/ETO-2 has a
role in controlling erythropoiesis and megakaryopoiesis. In
this context, MTG16/ETO-2 is incorporated in Ldb1 (LIM
domain- binding protein 1) and TAL1 (T-cell acute lym-
phocytic leukemia protein 1) containing transcription fac-
tor complexes [5,8,20,21], mediating transcriptional
suppression. As a heteromer with MTG16, also MTGR1
complexes with TAL1 in erythroid cells, enhancing tran-
scriptional repression [10]. The ETO-2 recruitment within
nuclear complexes may determine the onset of terminal
erythroid/megakaryocytic differentiation [5], while the
downmodulation of MTG16/ETO-2 at late stages of ery-
thropoiesis suggests that decreased transcriptional repres-
sion is necessary for late, terminal erythroid differentiation
to occur. For example, in erythroid MEL cells, induction of
differentiation is accompanied by dissociation of nuclear
protein complexes concomitant with a decrease in the rela-
tive level of ETO-2 [8]. Moreover, shedding the negative
regulator ETO-2 [21] transforms the Ldb complex into a
positive regulator of final erythroid differentiation, support-
ing the notion that multi-protein complexes may keep ery-
throid target genes suppressed until corepressor ETO-2 is
eliminated at final differentiation [21]. Similarly, in mega-
karyopoiesis the ETO-2 expression is restricted to imma-
ture cells consonant with a function in repression of genes
that should be only terminally expressed [22]. Finally, a
physiological hematopoietic role for MTG16 has been pro-
ven by results from targeted disruption of murine MTG16
(ETO-2) [23]. Although no complete block in hematopoie-
tic differentiation was discovered by ETO-2 knockout, a
requirement was demonstrated for ETO-2 in fate decisions,
proliferation and stress- dependent hematopoiesis. As a
corroboration of functional differences between ETO
homologues, targeted disruption of MTGR1 showed no
phenotypic consequences for hematopoiesis [24].
Endogenous cell-type-specific hematopoietic expres-
sion of the ETO homologues [18] suggests differences in
gene regulation. The ETO promoter is regulated by the
GATA transcription factor in erythroid/megakaryocytic
cells [25]. We now examined functional promoter ele-
ments upstream of the coding sequences for MTG16
and MTGR1. A critical role in transcriptional regulation
was shown for an evolutionary conserved GATA bind-
ing site of the MTG16 promoter. In contrast, MTGR1
has a strong TATA-less promoter with multiple GC
box-rich regions of possible importance for constitutive
expression. Our results show that the ETO homologue
promoters are regulated differently, consistent with cell-
type- specific expression.
Results
Identification of transcriptional start site and sequence
analysis of proximal promoters of MTG16 and MTGR1
The MTG16 corepressor is associated with developing
hematopoiesis and control of erythropoiesis/megakaryo-
poiesis. However, transcriptional factors regulating the
expression of the MTG16 and MTGR1 genes have not
been identified. Therefore, we tried to discover the impor-
tant cis-acting regions and trans-acting factors regulating
expression in hematopoietic cells. First, to find the posi-
tion of the transcriptional start site for MTG16, we per-
formed 5’- rapid amplification of cDNA-ends (RACE).
MTG16-cDNA amplified from erythropoietic HEL cell
mRNA showed a complete sequence match with a region
of MTG16a transcript (NCBI Ref. Seq: NT_010542.15).
The transcription start site (TSS) was determined at -176
bp upstream of the translation start codon ATG at +1
(Figure 1A). The translation initiation in MTG16b is
located further downstream to that of MTG16a as deter-
mined by alignment of mRNA sequence of MTG16a
(NM_005187.5) and MTG16b (NM_175931.2). Inspection
of the proximal promoter upstream of the transcription
start site start (-176 bp) revealed several consensus binding
elements (Figure 1A) such as potential ETS1 binding sites
at -491 and at -419; SP1 binding sites at -425 and at -316;
GATA binding sites at -356 and at -301; MZF1 sites at
-251 and at -191; TFAP2A at -389 (Figure 1A). No canoni-
cal TATA or CCAAT boxes were detected in the region
near the transcription start.
However, a conserved GC box close to the transcrip-
tional start site (Figure 1A) may regulate transcriptional
initiation. Sequence comparisons showed the GATA
binding site at -301 to be conserved between eight spe-
cies (Figure 1B).
The transcription start site for the MTGR1 gene (NCBI
Ref. Seq: NM_001032999.2) is present at -146 bp
upstream of the translation start codon [16]. As for
MTG16, the proximal promoter of MTGR1 lacks canoni-
cal TATA and CCAAT boxes. However, the region
between -285 to -170 bp contains multiple GC motifs
showing strong homology with the classical GC box,
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–668 AAGGGGTGCTGGGGAAAGCTCGGCTGACTGAGGGCTAGCGGAGAGGGAGGA 
 
–617 CACCCCCAGATACCCCAGGCTGAAGGAAGGGCCAAGCCCTGGGGGGAAGAT 
 
–566 GGGTGGGCGGGACAGGCCAAGGGCTCTGGGCCAGGATGGAGCTGCCCTCAG 
 
–515 GCCTGCACACCTGCCCTGGGGCCGAGGAAACACATGCCCAGTGGCCACGCT 
 
–464 GTAGGGCTCAGGGTGGGTGGGACGTCACCAGAGCTGCCTGGGAGGAGGAAG 
 
–413 TTGTTGGAAGGTCAAACCGGAATGGCCCGAGGGAAGGCCGCGCAGGGCAGG 
 
–362 GCCCCAGATGGTTCCTGTCAGGGAAGTGGCGGGCGCAGCTGCAGGCCTCCG 
 
–311 GCCCCGGCATTATCACGGGGACACAGCTGGCTGCCTCACCCGCAGGCTGCA 
 
–260 GGGAGACCTTCCCCAGCCTGCAGCCCCAGGCCCGCCCCGCGTCACATGAGC 
 
–209 CCCAGGGCTCCCACCCCCTCCCCAGGGCAGAGGACACCCAGTTGGTGGCCG 
 
–158 GGAGGGCCTCGGCTTTCCAGGGACAGAGGCCCAACTCCAGGACGCCCCAGC 
 
–107 TGGCCCAGCCCCTCCTCTTTCCCTCAAGGCTGCAGGAGGTCGGGAAAGGCA 
 
–56  GTCCTGGTAGAGGCCTGTCCTGGGCTCCAGGTTGGCCCCTGAGGGTGGCCC 
 
–5   TCCTCATGCCGG 
SP1 –425  ETS 1–419 
ETS 1 –491 
TFAP2A –389 
GATA –356  SP1 –316 
GATA –301
MZF1 –251 
MZF1–191 
+1 
TSS 
GC-Box 
 
 
Human           CAGGCCTCC--GGCCCC---GGCATTATCACGGGGACACAGCTGGCTGCCTCACCC--GC 
Chimpanzee      CAGGCCTCC--GGCCCC---GGCATTATCACGGGGACACAGCTGGCTGCCTCACCC--GC 
Orangutan       CAGGCCTCC--GGCCCT---GGCATTATCACGGGGACACAGCTGGCTGCCTCACCC--GC 
Gorilla         CAGGCCTCC--GGCCCC---GGCATTATCACAGGGACACAGCTGGCTGCCTCACCC--GC 
Rhesus          CAGGCCTCC--GGCCC-------ATTATCACAGGGACACAGCTGGCTGCCTCACCC--GC 
marmoset        CAGGCCTCG--GGCC-----GGCATTATCACGGGGACACAGCTGGCTGCCTCGCCC--AC 
Mouse           CAGGCCCCC--GACCCCCACCGCATTATCACTGTGACACAGCTGGCTGCCTCACCCCTGA 
Rat             CAGGCCCCCCCGACCCCCACCGCATTATCACGGCGACACAGCTGGCTGCCTCACCCCTGA 
****** * * ** ******** * ****************** ***
GATA 
Figure 1 Localization and structure of MTG16 promoter.( A) Nucleotide sequence of the MTG16 promoter. Identification of transcription start
site (TSS) and amplification of the promoter was performed as described in Methods. Nucleotide +1 is the translational start site (ATG). Putative
consensus binding sites for transcription factors identified with MatInspector http://www.genomatix.de//matinspector.html and http://jaspar.
genereg.net/ are marked. The promoter lacks TATA and CCAAT boxes, but a GC box (underlined) close to the TSS may be important for start site
utilization. (B) Homology search was performed for a stretch of sequence from -251 to -499 human sequencewith NCBI nucleotide blast (Blastn)
programme in database for “whole-genome shotgun reads” (wgs) and an evolutionary conserved GATA site was identified (marked between
straight lines). The following accession numbers appeared containing homologus sequences, Chimpanzee, b| AACZ03106631.1|; Orangutan gb|
ABGA01087101.1|; Gorilla, emb| CABD02143420.1|; Rhesus Monkey, gb|AANU01214553.1|; Marmoset, gb|ACFV01163109.1|; Mouse, ref|NT_078575.6|
Mm8_78640_37; Rat, ref|NW_047536.2|Rn19_WGA2058_4. The homology sequences were also found at http://genome.ucsc.edu/cgi-bin/hgBlat.
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to compose multiple binding sites for SP1. In addition,
ETS1 sites are noted at -335 and -276 as well as a YY1
potential binding sites at -301 bp. The different composi-
tion of the proximal promoters of MTG16 and MTGR1
suggests that they are under distinct regulatory mechan-
isms. While the promoters of both genes lack classical
TATA or CCAAT boxes, the presence in the MTGR1
promoter of multiple SP1 sites and a CpG island from
-450 to -1 bp covering the transcriptional start site (data
not shown) indicate characteristics of a housekeeping
gene.
Functional evaluation of MTG16 promoter
We cloned a -820 to -57 bp region (translational start
codon at +1) of the sequence upstream of the transcrip-
tion start of the MTG16 for determination of transcrip-
tional activity. The cloned region was inserted upstream
of the luciferase reporter gene in promoterless pGL3/
Basic vector (Promega) to give the pGL3/-820 to -57
plasmid, which was transfected into hematopoietic cell
lines and luciferase activity was determined and normal-
ized as described in Methods. pGL3/-820 to -57 showed
an approximately 4-fold increased reporter signal as com-
pared to pGL3/SV40-promoter in erythroid HEL cells
(Figure 3) indicating strong transcriptional activity in
cells expressing the endogenous MTG16 gene. The
MTG16 luciferase reporter also showed a strong signal in
other erythroid and in megakaryocytic cell lines investi-
gated (Figure 3). However, no direct correlation was
observed between luciferase activity and MTG16 tran-
scripts in erythroid and megakaryocytic cell lines. Differ-
ences in cellular environment and regulatory elements
outside the cloned promoter that modulate endogenous
gene expression could explain the lack of direct correla-
tion between promoter activity and gene expression. Pro-
myelocytic HL-60 and acute myeloid leukemia Kasumi-1
cells showed only low luciferase activity; lymphoblastoid
Raji cells and monkey kidney COS cells lacked reporter
activity. The latter results correlate with low MTG16
transcript levels.
A GATA consensus binding site is critical for MTG16
promoter function in erythroid/megakaryocytic cells
In order to identify important cis regulatory elements, a
series of constructs was produced by sequential deletions
from the 5’ e n do ft h e- 8 2 0t o- 5 7b pr e g i o ns h o w ni n
Figure 4. The deletion constructs were incorporated
upstream of the luciferase reporter gene in promoterless
pGL3/Basic resulting in the pGL3 -820-57, pGL3 -668-57,
Figure 2 Localization and structure of MTGR1 promoter. Nucleotide sequence of the MTGR1 promoter. The promoter of MTGR1 was amplified
by PCR as described in Methods. Nucleotide +1 is the translational start site (ATG) and transcription start site at -176 is marked (TSS). The MTGR1
promoter lacks TATA and CCAAT boxes but is GC-rich with multiple SP1 binding sites. Putative consensus binding sites for transcription factors
identified with MatInspector http://www.genomatix.de//matinspector.html and with http://jaspar.genereg.net/ are marked.
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57, and pGL3 -219-57 reporter constructs, which were
transfected into erythroid HEL/TF-1, erythroid/megakar-
yocytic UT-7 and megakaryocytic MEG-01 cells. Deletion
of the region from -820 to -668 did not reduce the tran-
scriptional activity of the promoter, while extended 5’-
deletions caused a prominent decrease in luciferase activity
(Figure 4). We conclude that the region between -668 and
-57 bp is likely to contain the major regulatory cis-ele-
ments of the proximal MTG16 promoter, as it was the
smallest fragment created with retention of full transcrip-
tional activity (Figure 4).
As noted in Figure 1A potential ETS1, SP1, GATA and
MZF1 binding sites are detected in the proximal MTG16
promoter. We examined whether these binding sites con-
tribute to promoter transactivation using site-directed
mutagenesis. Most notably, disruption of the GATA-301
site led to a 4 to 10-fold reduction in luciferase reporter
gene activity in either HEL, TF1, UT-7 or MEG-01 cells
relative to intact MTG16 promoter (P < 0.0001) (Figure 5),
indicating this GATA site as an important cis-factor for
MTG16 gene expression. Furthermore, the GATA -301
site is highly conserved among species (Figure 1B) support-
ing its functional importance. Moreover, GATA factors are
known to play an important role in erythroid/megakaryo-
cytic differentiation [26-28]. Our results suggest that the
GATA -301 site may be involved in transcriptional activa-
tion in erythroid/megakaryocytic cells.
The GATA-301 site is necessary but not sufficient for
transactivation of the MTG16 promoter as some deletion
constructs (-359, -339) that retain the GATA -301 site do
not retain transcriptional activity (Figure 4). However, all
mutation experiments were done with the longer -668
construct and its promoter activity was blocked comple-
tely by mutation of the GATA-301 site. An element
upstream of the GATA-301 site that cooperates with
G A T Ab o u n dt o- 3 0 1m i g h te x p l a i no u rr e s u l t s .H o w -
ever, no such element was identified as disruption of all
upstream potential binding sites that were identified e. g.
the SP1 -425, ETS1 -491, ETS1 -419, SP1 -316, and
GATA -356 sites did not affect the reporter signal (data
not shown). Disruption of the MZF1 -191 sites down-
stream of the GATA-301 site did not affect the luciferase
signal either (data not shown). Mutation of the down-
stream MZF1 - 251 increased the signal except in HEL
cells (data not shown), suggesting that this site possibly
mediates binding to some transcriptional repressor.
Figure 3 Reporter gene analysis of the MTG16 promoter.
Promoter activity in different cell lines. pGL3 -820-57 (-820) was
transfected to indicated cell lines and luciferase activity was
determined as described in Methods. The relative MTG16 mRNA
expression of the cell lines is also given. Kasumi, HL-60, Raji and
COS cells show both the lowest reporter signals and the lowest
MTG16 mRNAs.
Figure 4 Functional analysis of the MTG16 promoter by
sequential 5’-deletion. The following 5’deleted reporter constructs
were generated from the pGL3 -820-57 (-820) construct and
examined after expression in erythroid HEL/TF-1, erythroid/
megakaryocytic UT-7 and megakaryocytic MEG-01cells: pGL3 -668-57
(-668), pGL3 -512-57 (-512), pGL3 -359-57 (-359), pGL3 -339-57 (-339),
pGL3 -299-57 (-299) and pGL3 -219-57 (-219). Promoterless pGL3/
basic and the pGL3/SV40-promoter are used as negative and
positive control, respectively. The luciferase activity was normalized
against pGL3/SV40- promoter activity. Results are shown for 3 to 5
separate transfections; bars represent the mean and the error bars
show SEM.
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the MTG16 promoter
The finding that destruction of the conserved GATA
(-301) site reduced gene promoter activity (Figure 5) sug-
gested binding of trans-acting factors. Therefore, Electro-
phoretic Mobility Shift Assays (EMSA) and antibody
supershift assays were performed to examine whether the
-301 site binds GATA protein in vitro. A double-stranded
biotin-labeled oligonucleotide probe (see Methods) was
prepared for the core consensus GATA -301 site, the
sequence and location of which is shown in Figure 6. The
oligonucleotide probe was incubated with nuclear
extracts prepared from HEL, TF-1, UT-7 or MEG-01
cells to examine interactions between probe and proteins
in vitro. Nuclear extract proteins from all cell types
showed a shift, indicating binding of protein to the bioti-
nylated probe (Figure 6). Binding was specific, as shown
by absence of shift in the presence of excess unlabeled
competitor probe. Protein bound to the GATA-301
probe was “super-shifted” by anti-GATA-1 antibody, but
not with control anti-CD63 antibody (Figure 6). Thus,
our results demonstrate that GATA-1 can bind to the
consensus GATA-binding site (-301) within the MTG16
promoter. No supershift was observed by anti-GATA-2
antibodies (Figure 6) despite testing of several different
antibodies (data not shown), suggesting lack of strong
binding of GATA-2 to the consensus site. This finding is
similar to previous results from the characterization of
the ETO promoter, in which a GATA-site binds GATA-
1 but not GATA-2 [25].
In addition to the specific shift, another band is clearly
visible in the EMSA (Figure 6). This band-shift is unspe-
cific since it is unaffected or only weakly affected by the
competitor probe. However, it obviously contains
GATA-1 protein as it is lost by supershifting with anti
GATA-1 (Figure 6).
The SP1 -425 and the MZF1 -251 binding sites of the
MTG16 promoter were also examined by EMSA. No
supershifting was observed by appropriate antibodies sug-
gesting lack of binding of these transcription factors to the
respective consensus binding sites (data not shown).
Chromatin immunoprecipitation (ChIP) was used to
determine whether GATA-1-2 bound to the putative
MTG16 gene promoter in vivo. The assays were carried
out with chromatin isolated from HEL, TF-1, UT-7 or
MEG-01 cells and antibody towards chromatin-bound
GATA-1 or GATA-2. Precipitated DNA was identified
by PCR amplification of the MTG16 promoter fragment
with gene specific oligonucleotides. By the use of primers
specific for the -358 to -252 region, which flank the con-
served GATA (-301) site, a 107 bp PCR product was gen-
erated using precipitation with either anti-GATA-1 or
anti-GATA-2 (but not with anti-actin antibody or with
no antibody, serving as negative controls) of all the cell
lines examined (Figure 7). Control precipitation with
anti-GATA-1 or anti-GATA-2 and amplification of a
downstream control region was negative. Thus, specific
amplification was achieved after precipitation with both
anti-GATA-1 or anti-GATA-2.
Taken together, the results from EMSA/supershift
assays demonstrate GATA-1 binding in vitro to the
GATA -301 binding site and results from ChIP assays
demonstrate binding in vivo of both GATA-1 and
GATA-2 to the putative MTG16 promoter. This result
further supports a functional role at least for GATA-1
in activation of the MTG16 promoter, consistent with
the results of the mutagenesis studies shown in Figure 5.
Overexpression of GATA-1
GATA-1 was transiently overexpressed to examine its
effect on co-transfected MTG16 promoter activity in
erythroid/megakaryocytic cells. The reporter signal was
increased by overexpression in megakaryocytic MEG-01
cells (p < 0.05) (Figure 8). The specificity of this result
is supported by lack of impact by GATA-1 overexpres-
sion on the Renilla control (data not shown).
Repression of GATA-1 by siRNA and inhibition of GATA-1
transcriptional activity with HERP2 leads to decreased
MTG16 promoter activity
To verify a role of GATA-1 in MTG16 expression, siRNA
was transfected into HEL cells as described in Methods.
Figure 5 Functional analysis of putative transcription factor
binding sites in the MTG16 promoter. Putative Sp1 (-425), GATA
(-301) and MZF-1 (-251) sites in the -668-57 (-668) promoter were
individually destroyed by site directed mutagenesis as decribed in
Methods. Erythroid HEL/TF-1, erythroid/megakaryocytic UT-7 and
megakaryocytic MEG-01cells were transfected and luciferase activity
was determined. The pGL3/basic and pGL3/SV40-promoter are used
as negative and positive control, respectively. The luciferase activity
of mutated MTG16 promoter is normalized against luciferase activity
of wildtype MTG16 promoter.
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approximately 50% of both GATA-1 and MTG16 mRNA
levels and the results were confirmed on the protein
levels (Figure 9), indicating a role of GATA-1 in MTG16
transcriptional regulation. Three different siRNA con-
structs, all bioinformatically (Rosetta algorithm, SIGMA)
designed to minimize off-target effects were used. How-
ever, only one resulted in a robust suppression of GATA-
1 protein. Off-target effects can therefore not be
excluded. However, in combination with our results from
reporter experiments, EMSA, ChIP, and overexpression,
we believe that we can draw the conclusion that GATA-1
is a positive trans-acting factor on the promoter. Addi-
tional support for a role of GATA-1 was obtained by use
of the basic helix-loop-helix transcription factor HERP2,
which shows physical interaction with GATA-1 and
represses GATA-1-mediated transcriptional activation
[29]. Both erythroid and megakaryocytic cell lines
cotransfected with HERP2 showed strong inhibition of
the MTG16 promoter reporter (Figure 10) consistent
with a role of GATA-1 in transcriptional activation of
MTG16.
Figure 6 Detection of DNA-protein interactions using electrophoretic mobility shift/supershift assays in vitro of consensus binding
sequences in the 5’promoter of MTG16 and nuclear extracts. The following sequence of the oligonucleotide probe was used in EMSA for
the conserved GATA (-301) core consensus site (red): GATA-301 probe 5’- CCCGGCATTATCACGGGGACAC. Results are given for HEL/MEG-01/
TF-1/UT-7 cells. Primary DNA-nuclear protein interactions are shown by arrows marked shift; DNA- nuclear protein-antibody interactions are
shown by arrows marked supershift. All cell lines tested showed identical. A shift is shown for the GATA -301 probe that is competed for by
excess unlabelled probe (competitor) (3) indicating binding of nuclear extract protein to the biotinylated probe that containing the the GATA
-301 sequence. Proteins bound to the probe were “super-shifted” by antibody to GATA-1 (4) but not with antibody to GATA-2 (5). All
experiments were repeated at least twice.
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We cloned a -989 to +52 bp region (translational start
codon at +1) for examination of transcriptional activity.
The cloned region was inserted upstream of the lucifer-
ase reporter gene in promoterless pGL3/Basic vector to
give the pGL3/-989 to +57 plasmid, which was trans-
fected into hematopoietic cell lines and luciferase
Figure 7 Chromatin immunoprecipitation (ChIP) assay for
examining interactions in vivo of consensus binding sequences
in the 5’promoter of MTG16. The forward and reverse primers
used to amplify the proximal promoter region from -358 to -252
(primers A, solid arrows) and forward and reverse primers for a
downstream region from 1700 to 1835 as control (primers B,
dashed arrows) are shown. ChIP assays were carried out as
described in Methods using chromatin isolated from erythroid HEL/
TF-1, erythroid/megakaryocytic UT-7 and megakaryocytic MEG-
01cells. PCR products were separated on a 2% gel and
representative results are shown. Lane 1-2, no antibody and primers
A or B; lanes 3-4, actin antibody and primers A or B; lanes 5-6,
genomic DNA and primers A or B; lanes 7-11, GATA-1(top) or GATA-
2 (bottom) antibody and primers A or B (lane 11). By use of the
specific primers, a PCR product is generated both from the anti-
GATA-1 and the anti- GATA-2 immunoprecipitated chromatin. No
amplification is seen without antibody or in the presence of anti-
actin. All experiments were repeated at least twice.
Figure 8 Effects on the MTG16 promoter activity of GATA-1
overexpression. MEG-01 cells were co-transfected with 15 μg
MTG16 -668 to -57 bp promoter plasmid and increasing amounts of
GATA-1 plasmid. The luciferase activity is normalized against Renilla
and the activity of the MTG16 -668 to -57 bp promoter. The MTG16
promoter is activated by GATA-1 overexpression. The data are from
3 separate experiments. Bars represent the mean and the error bars
show SEM. Statistically significant differences are marked by star.
Figure 9 Effects on the MTG16 promoter activity of GATA-1
siRNA. Transfection was as described in Methods. The relative
mRNA expression of GATA-1 (black bar) and MTG16 (white bar) is
given for HEL cells (wt), HEL cells transfected with non silencing
scrambled control siRNA (control si) and HEL cells transfected with
siRNA for GATA-1 (GATA-1 si). The protein expression of GATA-1 and
MTG16 are shown with GAPDH as acontrol of equal loading. The
experiments were performed in triplicate. Bars represent the mean
and the error bars show SEM.
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Methods. An approximately 2-fold luciferase signal in
HEL cells, as compared to the positive control pGL3/
promoter, indicated strong transcriptional activity of the
cloned region (data not shown). Upon transfection of
the shortest luciferase construct with full promoter
activity (pGL3 -499 to +52 bp) (see Figure 11 below) to
a panel of hematopoietic cell lines, different activities
were revealed (Figure 12). As with the MTG16 promo-
ter, the strongest activity was found in HEL cells, but
the activity patterns between the two promoters were
not uniform (compare Figure 3 to Figure 12). The
MTGR1 promoter construct produced a signal in all cell
lines examined except for COS cells. All cell lines exam-
ined expressed endogeneous MTGR1 mRNA supporting
ubiquitous expression (Figure 12).
To define the promoter in more detail, a series of con-
structs was generated by sequential deletions from the
5’end of the -989 +52 bp region after which transcriptional
activity was analyzed in HEL cells (Figure 11). Deletion to
-499 did not affect transcriptional activity, but further
deletion reduced the luciferase reporter expression. Thus
the sequence from -499 to +52 bp retained full transcrip-
tional activity and therefore is likely to contain the core
proximal MTGR1 promoter. Further sequential 5’ dele-
tions of the -499 to +52 bp region resulted in a step by
step decreasing luciferase reporter signal (Figure 11) sug-
gesting cooperation between factors binding to different
regions of the promoter.
Site-directed mutagenesis was used to examine whether
potential transcription factor binding sites contributed to
promoter transactivation. The -308 to +52 bp region
retains approximately two thirds of the transcriptional
activity of the fully active promoter as was shown in
Figure 11. This region is GC box-rich with 9 SP1 consen-
sus binding sites (Figure 2) located immediately upstream
of the transcription start site at -146 bp consistent with
the housekeeping gene character of MTGR1 with ubiqui-
tous expression. However, disruption of individual SP1
sites; SP1-285, SP1-243, SP1-229, SP1-225, SP1-213, SP1-
206, SP1-192, SP1-178, SP1-170; did not affect reporter
gene activity relative to intact MTGR1 promoter (data
not shown), suggesting that SP1 is not important for pro-
moter activity. However, it is possible that multiple active
SP1 binding creates a redundancy in SP1 binding and
elimination of several SP1 binding sites is needed to
reveal their functional relevance. Disruption of the -335
ETS1, the -276 ETS1 and the -301 YY1 sites did also not
affect promoter activity (data not shown). Overall, our
results indicate that a GC-box-rich sequence with multi-
ple SP1 sites is important for transcriptional regulation of
MTGR1 promoter.
AML1-ETO represses MTG16 and MTGR1 gene reporters
The AML1-ETO fusion protein, which is a gene product
of t(8;21) of acute leukemia [14,15] binds the promoter
region of many genes causing transcriptional suppression
[30]. AML1- ETO has been shown to suppress an ETO
promoter reporter in erythroid/megakaryocytic cells [25].
Therefore, AML1-ETO was transiently expressed in HEL
Figure 10 Inhibition of the MTG16 promoter activity through
inhibition of GATA-1 by HERP2. TF-1, HEL, UT-7, or MEG-01 cells
were co-transfected with 10 μg MTG16 -668 to -57 bp promoter
and the HERP2 plasmid construct. White bars show MTG16 -668 to
-57 bp promoter activity without HERP2. Black bars show activity
after co-transfection with HERP2, relative to the luciferase activity of
the MTG16 -668 to -57 bp promoter in the absence of HERP2
(white bars). All cell lines examined demonstrated repression of
GATA-1 driven MTG16 luciferase promoter. Renilla was not
affetected by HERP2. The experiments were performed in triplicate.
Bars represent the mean and the error bars show SEM.
Figure 11 Reporter gene analysis of the MTGR1 promoter.
Functional analysis by sequential 5’-deletion. The 5’deleted MTGR1
reporter constructs -989 to +52 (-989), -656 to +52 (-656), -499 to
+52 (-499), -308 to +52 (-302), -257 to +52 (-257), -207 to +52 (-257),
and -145 to +52 (-145) were examined after expression in HEL cells.
The transcriptional activity is retained by the -499 to +52 bp region
indicating the location of the proximal MTGR1 promoter. The pGL3/
basic and pGL3/SV40-promoter are used as negative and positive
control, respectively in (A) and (B). The luciferase activity was
normalized against pGL3/SV40-promoter activity and is shown for 3
to 5 separate transfections; bars represent the mean and the error
bars show SEM.
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and MTGR1 promoter reporters. In both cases the repor-
ter was strongly repressed in a dose-dependent manner by
AML1-ETO (Figure 13). This finding is not directly con-
sistent with the inhibition observed in vivo in AML1-
ETO-positive Kasumi cells of only MTG16 (Figure 3) but
not MTGR1 transcripts (Figure 12) suggesting influence of
cell-specific contexts.
Discussion
The negative transcriptional regulator ETO was originally
discovered as the 3’ participant in the leukemia chromoso-
mal translocation t(8;21) [31]. Now, ETO and its homolo-
gues MTG16 and MTGR1 are known to be involved in
transcriptional regulation of genome-wide targets. To
explain cell-type-specificity of ETO homologue expression
and function [18] exploration of promoter regulation is
warranted. The human ETO proximal promoter is regu-
lated by the GATA-1 transcription factor in an erythroid/
megakaryocytic-specific manner [25]. Here, we continued
to identify essential cis-acting elements and trans-acting
factors also of the promoters of MTG16 and MTGR1
within human hematopoietic cells.
MTG16 promoter regulation
TATA and CAAT-like promoter motifs facilitate interac-
tions with general transcription factors and are thus
involved in initiation of transcription. The proximal
MTG16 promoter investigated lacks these motifs. GC-
boxes are known to regulate the utilization of start sites in
TATA-less promoters [32-35]. Therefore, the conserved
GC-box situated close to start site (Figure 1A) may be
involved in transcriptional initiation. Among hematopoie-
tic cell lines, the promoter activity was strongest in the
erythroid HEL/TF-1, erythroid/megakaryocytic UT-7 and
megakaryocytic MEG-01 cells consistent with a role of
MTG16 in erythropoiesis/megakaryopoiesis [5,8,20,21].
Deletion analysis of the proximal MTG16 promoter
defined a 492 bp region upstream of the transcription start
Figure 12 MTGR1 promoter activity in various cell lines. pGL3/-
499 to +52 (the shortest construct with full promoter activity) was
transfected to indicated cell lines and luciferase activity was
determined as described in Methods. The relative MTGR1 mRNA
expression of the cell lines is also given. The promoter shows a 1 to
2.5-fold increased reporter signal in most cell lines. MEG-01, HL-60
and COS cells show both the lowest reporter signals and the lowest
MTGR1 mRNAs.
Figure 13 Effects of AML1-ETO on the MTG16 and MTGR1
promoter reporter. Erythroid HEL cells were co-transfected with 15
μg MTG16 -668 to -57 bp promoter plasmid (-668) or MTGR1 -499 to
+52 bp promoter plasmid (-499) and 0 to 1 μgo fAML1- ETO
plasmid. pGL3/Basic (Basic). pGL3/SV40 (SV40). The luciferase activity
is normalized against MTG16 -668 to -57 bp or MTGR1 -499 to +52
bp promoter. Both promoters are repressed in a dose-dependent
manner by AML-ETO. Western blotting shows exogeneous AML1-
ETO expression detected with anti-MTG. The experiments were
repeated three times with similar results.
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includes a potential GATA binding site (-301), which is
strongly conserved between species. Disruption of the
GATA -301 binding site, repressed transactivation of the
MTG16 promoter. The importance of this cis-acting bind-
ing site was confirmed by results from examination in
vitro with EMSA, which revealed specific GATA-1 bind-
ing. Further, in vivo binding of both GATA-1 and GATA-
2 to this region of the promoter was confirmed by ChIP/
PCR analysis. Taken together these results demonstrate
binding of the GATA-1 transcription factor to the MTG16
promoter and strongly support a role for GATA-1 in tran-
scriptional regulation of the MTG16 gene in hematopoie-
tic cells.
MTGR1 promoter regulation
A 499 bp region upstream of the translation start site of
MTGR1 was defined as sufficient for maximal activity in
erythroid HEL cells. Upon analysis using different cell
lines, we found that the promoter is active in most of
them, which is in agreement with ubiquitous presence of
native MTGR1 gene product. Furthermore, the lack of
classical TATA or CCAAT boxes, the presence of multi-
ple SP1 sites and a CpG island covering the transcrip-
tional initiation site of the MTGR1 promoter (Figure 2)
are similar to characteristics of a housekeeping gene [36],
expected to be generally active in a non-tissue specific
manner. Few potential binding sites for known transcrip-
tion factors were found in the -499 promoter, rather a
GC-box-rich sequence stretch with multiple SP1 binding
sites is a prominent part of the promoter. Importantly,
the GC-box-rich region was responsible for most of the
transcriptional activity. However, we were not able to
inhibit promoter activity by the elimination of individual
SP1 binding sites. Possibly, individual SP1 binding sites
may be equally involved in guaranteeing constitutive
MTGR1 expression. Further 5’deletion of the -499 pro-
moter region showed gradually decreasing promoter
activity observed upon successive deletions, indicating
transcriptional cooperation between promoter sequences
consistent with cooperating SP1- binding sites.
ETO homologues in hematopoiesis
The regulation of both the ETO [25] and the MTG16
promoter (this work) by GATA-1 is consistent with a
role of human ETO/MTG16-mediated gene suppression
at a phase of erythropoiesis/megakaryopoiesis when
GATA-1 levels are high [37,38]. However, despite
shared trans-activation, MTG16 and ETO are differently
expressed in human hematopoiesis [18]; MTG16 is
downmodulated at late stages of erythropoiesis whereas
ETO is expressed transiently in (human) erythropoiesis.
Therefore, cell-type-specific expression of these ETO
homologues may be governed also by trans-activating
factors other than GATA. Although both MTG16 and
ETO are expressed in human erythroid cells [18] yet the
role of ETO in murine erythropoiesis is not yet sup-
ported [10].
GATA-1 and GATA-2 are expressed reciprocally during
development of the erythropoietic lineage, GATA-2
decrease is followed by GATA-1 increase [39]. GATA-2
seems to be essential for the development of early and
definitive erythropoiesis/megakaryopoiesis and GATA-1
for terminal erythroid/megakaryocytic maturation [26-28].
The present results are consistent with upregulation of
MTG16 as a result of rising GATA-1 levels. Furthermore,
results from genome-wide analyses [40] are consistent
with early GATA-2 induction of murine ETO-2 during
erythropoiesis. These analyses also showed that most
occupied sites are located away from promoters indicating
that GATA factors may be involved in long- range control
by occupancy at non-promoter regions.
Our finding of in vitro binding of GATA-1 but lack of
GATA-2 binding to the GATA -301 binding site raises
questions about the relative importance of GATA-1/
GATA-2 in MTG16 promoter regulation. GATA-2 is
reported to contribute in hematopoietic stem cell and
progenitor survival [41] and GATA-1 in erythroid cell
survival [42,43]. Furthermore, genetic complementation
studies show that GATA-1 can replace GATA-2 [44,45].
A lack of binding in EMSA experiments suggests that
GATA-2 may not be a primary transcription factor to
initiate nucleation of the transcription complex at the
MTG16 promoter. Possibly, GATA-2 has a weaker bind-
ing affinity than GATA-1. However, our finding in ChIP
assay of the binding of both GATA-1 and GATA-2 to
MTG16 promoter suggests that GATA-1 and GATA-2
cooperate. This is supported by results from in vivo stu-
dies by ChIP-seq with human K562 erythroleukemia cells
[40] showing chromatin occupancy by both GATA-1 and
GATA-2 at the conserved GATA motif corresponding to
t h e- 3 0 1s i t eo ft h eMTG16 promoter. In addition, a role
of GATA-2 in stimulating murine ETO-2 expression was
also suggested [40]. Thus, GATA-2 was found to occupy
a conserved GATA binding site in the murine erythroid
G1E cell, which lack GATA-1 expression; the occupied
murine site corresponds to the human -301 GATA bind-
ing site of MTG16 promoter. Overall, available data sug-
g e s tar o l eo fb o t hG A T A - 1a n dG A T A - 2i nMTG16
promoter activation.
Murine MTG16 (ETO2) is involved in erythroid pro-
genitor expansion [5], which is coupled to inhibition of
differentiation. This is also the case in megakaryopoiesis
where ETO2 represses inappropriate early expression of
terminal genes [22] coupled to restrained differentiation of
immature megakaryocytes. MTG16 and ETO show reci-
procal expression during in vitro-induced human erythro-
poiesis; MTG16 decreases and ETO increases during the
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lated by GATA-1, specific negative autoregulation of
MTG16 [40] may explain the difference. This is consonant
with a role for MTG16 in repressing genes associated with
terminal erythroid differentiation thereby inhibiting differ-
entiation and a role for ETO in repressing genes asso-
ciated with self-renewal and proliferation thereby
supporting erythroid differentiation.
Suppression of MTG16/MTGR1 promoter by AML1-ETO
The leukemic AML1-ETO fusion protein [14,15] binds to
the promoter region of a number of genes resulting in
transcriptional suppression [30]. However, some genes are
affected by AML1-ETO in an indirect manner and do not
bind the fusion protein directly [30,46]. The observed sup-
pression of the MTG16 and the MTGR1 promoter by
AML1-ETO is likely to be indirect as binding sites for
AML1 were not detectable on the promoters. Furthermore,
a potential mechanism for the MTG16 promoter inhibition
by AML1-ETO would be suppression of GATA-1 through
impaired acetylation [47]. Suppression of MTG16 is consis-
tent with the low MTG16 promoter reporter signal
observed in AML1-ETO-positive Kasumi cells, which
showed very low MTG16 transcripts (Figure 3), whereas
MTGR1 transcripts were high in this cell line (Figure 12).
AML1-ETO-mediated suppression of the ETO promoter
has also been reported [25] and suggested to facilitate the
AML1-ETO- induced block of erythroid lineage commit-
ment [47,48]. AML1-ETO-mediated repression of MTG16
may have a similar effect because of blocking MTG16/
ETO2-mediated erythroid progenitor expansion [5]. The
repression of all ETO homologue genes by AML1-ETO
may have a general role in inhibition of hematopoietic dif-
ferentiation in t(8;21) leukemia.
Conclusions
This work shows differences in promoter regulation
between MTG16 and MTGR1 that may explain differences
in hematopoietic expression of these genes. Evolutionary
conserved GATA binding sites are critical in transcrip-
tional regulation of both MTG16 (this work) and ETO
[25] promoters. The MTGR1 promoter has a GC box-rich
sequence with multiple SP1 binding sites, which may
secure transcriptional regulation and ubiquitous expres-
sion of this gene.
Methods
Cell Culture
Myelomonocytic U-937, erythroid HEL and TF-1,
megakaryocytic MEG-01 cells were grown in RPMI-
1640 medium supplemented with 10% Fetal Bovine
Serum (FBS) (Gibco BRL, Life Technologies, Rockville,
MD, USA); TF-1 cells also received 20 ng/ml GM-
CSF (R&D Systems, MN, USA). The erythroid/
megakaryocytic UT-7 cells were grown in MEM Alpha
modification medium with L-Glutamine and Nucleo-
sides (PAA Laboratories GmBh, Austria) supplemented
with 20% FBS and 30 ng/ml GM-CSF. The acute mye-
loid leukemia Kasumi-1, Burkitt’s lymphoma Raji, and
promyelocytic HL-60 cells were supplemented with
20% FBS. Monkey kidney COS cells were grown in
DMEM medium with 10% FBS supplemented with high
glucose (4.5 g/L) and L-glutamine.
Identification of the transcription start site of the MTG16
gene
The 5’-end (transcription start) of the mRNA was identi-
fied by 5’-RACE carried out with mRNA prepared from
HEL cells using Oligotex Direct mRNA mini Kit (Qiagen,
Hilden, Germany), using the First choice RNA Ligase
mediated (RLM)-RACE kit (Ambion Inc., TX, USA).
Nested PCR of RACE reactions was performed with adap-
ter primer 5’-CGCGGATCCGAACACTGCGTTTGCTG
GCTTTGATG-3’ and nested gene specific primer 5’-
GCCTTAGCTTTCCTGTCCACTGG-3’. RACE- products
were cloned into pGEM-T Easy Vector system (Promega
Corporation, WI, USA) and sequenced.
Amplification of MTG16 promoter region
A 1208 bp region upstream of the translation start (from
-1264 to -57 bp) was amplified from human genomic
DNA by PCR. The forward and reverse primers used were
5’-TGAGGCGGTACCACCTCCAGCCATGGCATC -3’
and 5’-TGCCTAGATCTACCTCCTGCAGCCTTGAGG
-3’, respectively. Regions corresponding to -905 to -57 and
-820 to -57 bp were amplified from the 1208 bp fragment
by nested PCR with forward primers 5’-T A T GG-
TACCGTGGGGGAGCCCTGCTGTCTCCACA -3’ (KpnI
restriction site underlined),5’- AGGCGGGAGGTACCTT-
GAGGACAGGTCAGG -3’ (KpnI restriction site under-
lined), and a common reverse primer 5’-TGCCTAGA
TCTACCTCCTGCAGCCTTGAGG -3’ (BglII restriction
site underlined).
Sequential 5’ deletions of the -820 to -57 bp promoter
region were generated by PCR from the cloned genomic
DNA as template to generate -668 to -57, the -512 to -57,
the -359 to -57 bp, the -339 to -57, the -299 to -57 and the
-219 to -57 regions. Forward primers were 5’-TAAGGTAC
CCTGGGGAAAGCTCGGCTGAC-3’,5 ’-TATGGTACC
CCTGCCCTGGGGCCGAGG -3’,5 ’-CCAGGTACCTCC
TGTCAGGGAAGTGGCGG-3’,5 ’-TATGGTACCGGGC
GCAGCTGCAGGCC
-3’,5 ’-T A T GGTACCTCACGGGGACACAGCTGGC-3’
and 5’-TATGGTACCATGAGCCCCAGGGCTCCCACCC
-3’ with KpnI restricton sites underlined. The common
reverse primer is the same as used for amplification of the
-1208 to -57 bp region. All sequences were verified by
sequencing.
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A5 ’ flanking region of 1965 bp from -1913 to +52 bp was
amplified from human genomic DNA by PCR. The for-
ward and reverse primers used were 5’-TATTGGTACCG-
CAACACCATGTCTGGCTAA -3’ (KpnI restriction site
underlined) and 5’- CTACAGATCTGCATTCACGCCC-
CACTTAC -3’ (BglII restriction site underlined), respec-
tively. Regions corresponding to -989 to +52, -656 to +52
and -499 to +52 bp were amplified from the 1965 bp frag-
ment by nested PCR with forward primers 5’-TTGCG
GTACCCTTCAAACTCCTGACCTCGTGA -3’ (KpnI
restriction site underlined), 5’- TTGCGGTACCCCCGGC-
CAACAGTTATTAAA -3’ (KpnI restriction site under-
lined), 5’- TTGCGGTACCTGTAATCCCTCCCCCTA
GCACT -3’ (KpnI restriction site underlined), and a com-
mon reverse primer 5’-CTACAGATCTGCATTCACGCC
CCACTTAC -3’ (BglII restriction site underlined).
Sequential 5’ deletions of the -499 to +52 bp promoter
region were generated by PCR from the cloned genomic
DNA as template to generate -308 to +52, the -257 to
+52, the -207 to +52 bp and the -145 to +52 regions.
Forward primers were 5’-TTGCGGTACCGTGCT-
TAATGGGAGCTGGTCT.-3’,5 ’-TTGCGGTACCGCGG
CGAGAGCGCGCGGCGGGGGCG -3’,5 ’-TTGCGGTA
CCGCCGGGGGCGGGGCGGGGCGCGGCC -3’ and 5’-
TTGCGGTACCGTGGTGGTGTCTGGTTAGCTC-3’,
with KpnI restricton sites underlined. The common
reverse primer is the same as used for amplification of the
-499 to +52 bp region. All sequences were verified by
sequencing.
Site-directed mutagenesis of transcription factor-binding
sites
Oligonucleotide primers including the desired mutations
were synthesized and used in two-step spliced overhang
extension PCR. The following potential MTG16 promoter
transcription factor binding sites were mutated: ETS1/
PU.1 sites at positions -491, 5’-AGGAAA-3’ changed to
5’-A TTCAA-3’; SP1 sites at positions -425, 5’-GGGAGG-
3’ changed to 5’-GTTCGG-3’; ETS1/SPI1 sites at positions
-419, 5’-AGGAAGT-3’ changed to 5’ -A TTCAGT-3’
TFAP2A sites at positions -389, 5’-GCCCGAGGG-3’
changed to 5’-GCCTTCGGG-3’; GATA/YY1 sites at posi-
tions -356, 5’-GATGGT-3’ changed to 5’-GACTTT-3’;
SP1 sites at positions -316, 5’-CTCCGGCCCC-3’ changed
to 5’-CTCCTTACCC-3’; GATA sites at positions -301, 5’-
TATCA-3’ changed to 5’-TGGTA-3’ and MZF1 sites at
positions -251 & -191, 5’-TCCCCA-3’ changed to 5’-
TAAACA-3’.
The following potential MTGR1 promoter transcription
factor binding sites were mutated: ETS1 sites at positions
-335, 5’-CTTCCG-3’ changed to 5’-CGTATG-3’;Y Y 1
sites at positions -301, 5’-CCCATT-3’changed to 5’-
CTTCTT-3’; SP1 sites at positions -285, 5’-CCCGG
CCCCA-3’ changed to 5’-C ACTGTCCCA -3’; ETS1 sites
at positions -276, 5’-CTTCCG-3’ changed to 5’-C G
TATG- 3 ’ SP1 sites at positions -243, 5’-CCCCCGCCGC-
3’ changed to 5’-C C C TTGCAGC -3’; SP1 sites at posi-
tions -229, 5’-CCCCGCCCGC-3’ changed to 5’-
CCTTGCACGC -3’; SP1 sites at positions -225, 5’-
CCCCGCCCCG-3’ changed to 5’-C C TTGCACCG -3’;
SP1 sites at positions -213, 5’-CCCCGCCCCC-3’ changed
to 5’-C C TTGCACCC -3’; SP1 sites at positions -206, 5’-
CCCCGCCCCG-3’ changed to 5’-C C TTGCACCG -3’;
SP1 sites at positions -192, 5’-CGCCGCCGCC-3’ changed
to 5’-C G TTGCAGCC -3’; SP1 sites at positions -178, 5’-
CGCCGCCGCC-3’ changed to 5’-C G TTGCAGCC -3’
a n dS P 1s i t e sa tp o s i t i o n s- 1 7 0 ,5 ’-CGCCGCCGCC-3’
changed to 5’-C G TTGCAGCC -3’. After subcloning into
promoterless pGL3/Basic reporter plasmid, all mutations
were verified by sequencing.
Luciferase reporter assays of MTG16 and MTGR1 promoter
MTG16 promoter was cloned into promoterless pGL3/
Basic reporter plasmid using firefly luciferase as reporter
to generate pGL3 -905-57, pGL3 -820-57, pGL3 -668-57,
pGL3 - 512-57, pGL3 -359-57, pGL3 -339-57, pGL3 -299-
57 and pGL3 -219-57 reporter constructs. Mutants were
cloned into the same reporter plasmid. Transient transfec-
tions of hematopoietic cell lines were performed by elec-
troporation as previously described by [49]. The pGL3/
SV40-promoter vector served as positive control and pro-
moterless pGL3/Basic vector as negative control. Renilla
luciferase, pRL/SV40 vector (Promega Corporation, WI,
USA) was used as internal control for transfection effi-
ciency. Thirtyfive μg pGL3 DNA were used for HL-60 tar-
get cells and 15 μg for HEL, TF-1, U937, UT-7, MEG-01,
Raji and Kasumi-1 target cells. COS cells were transfected
with 1.5 μg of DNA by use of Polyfect (Qiagen, Hilden,
Germany). Twentyfour hours after transfection, cells were
lysed and subjected to luciferase dermination using the
Dual luciferase reporter assay kit (Promega Corporation,
WI, USA). Firefly and Renilla luminiscense were quantified
(Run Promega Protocol, DLR-0-INJ) in a GLOMAX 20/20
Luminometer (Promega Corporation, WI, USA). Firefly
was normalized to Renilla luciferase as internal control for
transfection efficiency. Results are given as adjusted Rela-
tive Luciferase Units (AdjRLU) normalized to pGL3/pro-
moter (set to 1). Three to five independent transfections
were performed in each case and each sample was mea-
sured in triplicate.
Similarly, MTGR1 pGL3 -1913 + 52, pGL3 -989 + 52,
pGL3 -656 + 52, pGL3 -499 + 52, pGL3 -308 + 52, pGL3
-257 + 52, pGL3 -207 + 52 and pGL3 -145 + 52 reporters
were generated, transfected into cells and assayed as
described above.
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Twentyfour-well Falcon plates (Becton Dickinson, New Jer-
sey 07417, USA) were coated with 1 mg/ml retronectin
(Takara Bio inc, Verviers, Belgium) in PBS for two h at
room temperature. Excess retronectine was removed and
wells were blocked with 2% BSA in PBS for 30 min. After
removal of the supernatant, 50,000 HEL cells were added
per well in 600 μl RPMI medium containing 10% FBS and
20 nM phorbol 12-myristate 13-acetate (PMA) to generate
adherent cells by incubation at 37°C for 24 h. After wash-
ing with PBS transfection was carried out with 5 μM
siRNA using the N-TER transfection reagent (Sigma-
Aldrich Corp. St. Louis, MO USA) in RPMI without FBS.
After 4 h, 300 μl of RPMI with 20% FBS was gently added
and cells were incubated for 48 h. Eventually, gently rinsed
with PBS, tripsinized and examined by Western blotting.
The GATA-1 siRNA sequence was 5’-AGUUGAGG-
CAGGGUAGAGC-3’ (Oligo SASI_Hs02_00333089,
Sigma).
Inhibition of GATA-1 transcriptional activity by HERP2
The transcription factor HERP2 represses transcriptional
activation by GATA-1 [29] by physical interaction. To get
support for a role of GATA-1 in gene activation of
MTG16,H E L ,T F - 1 ,U T - 7 ,a n dM E G - 0 1 c e l l sw e r ec o -
transfected with 10 μg MTG16 pGL3 -668 luciferase
reporter and 10 μg HERP2 plasmid (kindly provided by Dr
N Goldfarb, Charlottesville, Virginia) and the reporter sig-
nal was measured after 24 h as described above for lucifer-
ase reporter assays. The results were normalized to the
luciferase activity of pGL3 -668 luciferase reporter.
Electrophoretic Mobility Shift Assay (EMSA) of MTG16
promoter
EMSA was performed as described previously [25]. The
potential GATA-1 sites at -301 was examined. The probe
sequence was biotin-5-CCCGGCATTATCACGGGGA-
CAC -3’. Nuclear extracts from HEL, TF-1, UT-7 and
MEG-01 cells were prepared as described by Andrews and
Faller [50]. One to two μl polyclonal anti-GATA-1 (Active
Motif, Carlsbad, CA, USA), monoclonal anti-GATA-2
(Santa Cruz Biotechnology Inc., CA, USA, sc-9008) or poly-
clonal anti-CD63 (sc-7080, Santa Cruz Biotechnology Inc.,
CA, USA) antibodies were added to the reaction mixtures.
Chromatin Immunoprecipitation (ChIP) assay of MTG16
promoter
ChIP was performed as described previously [25]. For IP, 4
μl of polyclonal anti-GATA-1 (Active Motif, Carlsbad, CA,
USA) or 0.8 μg monoclonal anti-GATA-2 antibodies
(R&D Systems, MN, USA) were used. Forward and reverse
primers for GATA sites were 5’-CAGATGGTTCCTGT-
CAGGGAAGTGGCG-3’ and 5’-AGGTCTCCCTG-
CAGCCTGCGGGTGAG-3’. Control forward and reverse
primers were: 5’-TAACACAGAGTACCCAGC-
CACTGTGC-3 ‘ and 5’-TGGTTGCACGGACA-
GAAGCCCCT-3’. Three different chromatin preparations
were used for each IP.
Quantitative real-time PCR
Real-time PCR was performed as described previously
[18]. Transcript levels were calculated from a standard
curve based on the Ct values of the samples,. Relative
quantification based on the ΔCt method [51] was used.
Normalization: ΔCt = Ct (sample) - Ct (HEL correspond-
ing DNA concentration). Relative quantification = 2
- ΔCt .
Immunoprecipitation (IP) and Western blotting
IP and Western blotting were performed as described
previously [52]. The following antibodies were used: poly-
clonal anti-GATA-1 (Active Motif, Carlsbad, CA, USA)
and polyclonal anti-GATA-2 (R&D Systems, MN, USA).
Bioinformatics
The cDNA sequences were analyzed by use of the NCBI
Blast program http://www.ncbi.nlm.nih.gov/BLAST/.
Conserved regions were searched by multiple alignment
to genomic sequences using ClustalW http://www.ebi.ac.
uk/Tools/clustalw2/index.html.
Potential transcription factor binding sites were exam-
ined with the MatInspector http://www.genomatix.de//
matinspector.html and the Jaspar database (Jaspar.genereg.
net).
Statistical analysis
The statistical significance between two samples was
determined by unpaired t-test in Prism Programme. Tri-
ple and single asterisk represents P < 0.0001 and P <
0.05, respectively.
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